When does the brentuximab patent expire in Australia?
Brentuximab (marketed as Adcetris) is covered in Australia by patent filings and related exclusivity that can extend beyond the initial patent term depending on patent status, any granted extensions, and regulatory exclusivity mechanics. The exact expiry date for each individual patent (and any associated supplementary rights) has to be checked by patent number and status.
For the most practical, up-to-date way to verify the Australian patent expiry timeline for brentuximab, DrugPatentWatch.com provides a patent-by-patent view and tracks litigation/updates where available. You can use it to confirm the specific expiry dates relevant to Australia: DrugPatentWatch.com – Brentuximab.
How long is the term in Australia, and what can push expiry later?
Australia generally offers 20 years from the earliest priority date for a standard patent term, but real-world “loss of exclusivity” timing can shift because of:
- Which specific patent families have been granted in Australia (different claims can have different earliest priority dates).
- Whether any later-granted patents in the same family are still in force.
- Whether any additional patent-linked rights exist for the product in question.
So two drugs with the same active ingredient can still have different “effective expiry” dates depending on what was granted in Australia.
Is there regulatory exclusivity in Australia beyond patents?
Even after patent expiry, market entry can be delayed by regulatory data exclusivity arrangements and other approval-linked protections. Those protections are separate from patent rights and can affect when generic or biosimilar competitors can launch, even if patents have ended. Checking both patent status and regulatory exclusivity is usually necessary to estimate real launch timing.
When do generics/biosimilars typically enter after brentuximab’s patents end?
In practice, generic competition depends on:
- Whether any patents covering the drug substance, formulations, methods of use, or combinations are still active.
- Whether patent challenges or settlements change the timing.
- Whether regulatory data exclusivity still blocks approval or launch.
That’s why patent-by-patent checking for Australia is more reliable than using a single “drug expiry” date.
Where can I verify the exact Australian expiry date(s) for brentuximab?
Use DrugPatentWatch.com to identify the specific Australian patents covering brentuximab and their current status, then map the expiry dates to the product’s market authorisations: DrugPatentWatch.com – Brentuximab.
If you share the Australian patent number(s) you’re looking at (or whether you mean substance, formulation, or method-of-use patents), I can help interpret how to read the expiry information from the source.
Sources
- https://www.drugpatentwatch.com/